Investorideas.com

Get investor ideas from our AI, cannabis, cleantech, crypto, gaming, mining, sports podcasts - be a guest or sponsor: call 800 665 0411


Share on StockTwits

Medical Device Company's Improved Fundamentals Offer Multiple Expansion Potential

Source: Streetwise Reports

September 8, 2021 (Investorideas.com Newswire) ROTH Capital Partners LLC commented in a research report that it is maintaining its "Buy" rating and raising its FY/22 revenue estimates for Dynatronics Corp. to $41 million after the firm pre-announced Q4/21 revenue figures that exceeded prior estimates.


Scott R. Henry, CFA of ROTH Capital Partners LLC commented in a September 3 research note that fundamentals are improving at medical device company Dynatronics Corp. (DYNT:NASDAQ), which designs, manufactures and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the U.S. and to 30 countries globally.

The analyst advised that Dynatronics recently announced preliminary Q4/21 revenues of $12.1 million, which exceeded ROTH Capital Partners estimates of $10.7 million.

Analyst Henry noted that the latest quarter's results support the case that the firm is on pace to surpass its FY/22 revenue estimates of $35 million. ROTH mentioned that it is likely though that the higher projected revenues will probably be offset by some pressure on gross margins.

The analyst advised; however, that "the key breakout event for revenue/EPS remains an M&A event (likely in the next 18 months, in our opinion)."

ROTH Capital indicated that it is incorporating the pre-announced data into its valuation model and has revised its Q4/21 total revenue estimates from $10.7 million to $12.1 million, of which, approximately $9.7M is expected to be generated from continuing products revenue. ROTH's model will also be adjusted to reflect Dynatronics' roughly $1.2 million in restructuring costs and one-time gains of around $6.1 million related to employee retention credits, a facility sale, and a Paycheck Protection Program (PPP) loan in Q4/21.

The analyst pointed out that the upturn in revenues suggests a rebound in Dynatronics' core business. With continuing product revenue hovering in the $10 million range in Q4/21, ROTH is raising its FY/22 revenue estimates for Dynatronics from $35 million to $41 million.

ROTH added that despite the increase in projected revenues, it believes that gross margins remain challenged. Therefore, for FY/22 it anticipates that gross margin will come in at 30% versus its prior estimate of 35%. The reason for the drop in margins in the report was attributed to a combination of factors including supply constraints, inflation costs, and lower historical sales volumes. ROTH stated that it expects gross margins to increase in subsequent years.

The report noted that Dynatronics is now cash flow neutral-to-positive, and, if it decided to pursue favorable acquisitions, that might serve as a strong catalyst for an EPS and share price breakout. The company indicated that at the end of Q3/21 it held about $4.5 million in cash on its balance sheet along with an additional untapped balance of around $4.5M on its credit line.

Dynatronics Corp. is a medical device company based in Eagan, Minnesota. The firm markets its branded Bird & Cronin, Hausmann, Physician's Choice, PROTEAM, and Solaris products in the U.S. to athletic and sports medicine trainers, orthopedists, physical therapists, hospitals, clinics, and consumers and others, as well as online.

ROTH Capital Partners advised that it is maintaining its "Buy" rating for Dynatronics Corp. with a 12-month price target $2.10 per share. The analyst explained that the ROTH's price target of $2.10/share was derived by "applying a ~1.3x multiple to forecasted FY/22 revenues of $41M (adjusted for net debt and future estimated dilution)." The company's shares trade on the NASDAQ under the symbol DYNT and closed for trading at $1.35/share on September 3, 2021.

Disclosure:

1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from ROTH, Initiating Coverage, Sept. 3, 2021

ROTH makes a market in shares of Dynatronics Corporation and as such, buys and sells from customers on a principal basis.

A Research Analyst and/or a member of the Analyst's household own(s) debt or equity securities of Dynatronics Corporation stock.

Shares of Dynatronics Corporation may be subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information and facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be used as a complete analysis of the company, industry or security discussed in the report. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors.

More Info:

Investorideas.com Newswire

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp


Follow Us on StockTwits






BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on Investorideas.com